Drug development in cardiovascular and metabolism

Novartis is focused on improving the lives of the hundreds of millions of people with cardiovascular and metabolic diseases. As a global leader in cardiovascular and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat high blood pressure and diabetes - both major public health issues.For more information visit http://www.novartis.com/about-novartis/our-businesses/cardiovascular-metabolism.shtml

The portfolio includes the following treatments for high blood pressure:

Diovan (valsartan), the world's most-prescribed angiotensin receptor blocker
Co-Diovan/Diovan HCT (valsartan and hydrochlorothiazide)
Exforge (amlodipine and valsartan), a single pill combining two leading high blood pressure medicines
Tekturna/Rasilez (aliskiren), the first and only approved direct renin inhibitor
Top products also include cholesterol-lowering agent Lescol (fluvastatin sodium) and the following treatments for type 2 diabetes:

Galvus (vildagliptin), a novel DPP-4 inhibitor
Eucreas (vildagliptin and metformin)